BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20196386)

  • 1. Final height of patients with classical congenital adrenal hyperplasia.
    Aycan Z; Akbuğa S; Cetinkaya E; Ocal G; Berberoğlu M; Evliyaoğlu O; Adiyaman P
    Turk J Pediatr; 2009; 51(6):539-44. PubMed ID: 20196386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Völkl TM; Simm D; Beier C; Dörr HG
    Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
    Manoli I; Kanaka-Gantenbein Ch; Voutetakis A; Maniati-Christidi M; Dacou-Voutetakis C
    Clin Endocrinol (Oxf); 2002 Nov; 57(5):669-76. PubMed ID: 12390343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
    Hauffa BP; Winter A; Stolecke H
    Klin Padiatr; 1997; 209(2):71-7. PubMed ID: 9113619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia.
    Bomberg EM; Addo OY; Kyllo J; Gonzalez-Bolanos MT; Ltief AM; Pittock S; Himes JH; Miller BS; Sarafoglou K
    J Pediatr; 2015 Mar; 166(3):743-50. PubMed ID: 25557963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation.
    Bonfig W; Pozza SB; Schmidt H; Pagel P; Knorr D; Schwarz HP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3882-8. PubMed ID: 19622620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
    Pijnenburg-Kleizen KJ; Thomas CMG; Otten BJ; Roeleveld N; Claahsen-van der Grinten HL
    J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1055-1063. PubMed ID: 31573958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
    Bonfig W; Bechtold S; Schmidt H; Knorr D; Schwarz HP
    J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia.
    Ciaccio M; Montiveros C; Rivarola MA; Belgorosky A
    Medicina (B Aires); 2002; 62(6):551-4. PubMed ID: 12532689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens.
    Rasat R; Espiner EA; Abbott GD
    N Z Med J; 1995 Aug; 108(1005):311-4. PubMed ID: 7644165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
    Bizzarri C; Improda N; Maggioli C; Capalbo D; Roma S; Porzio O; Salerno M; Cappa M
    Endocr Pract; 2017 May; 23(5):546-556. PubMed ID: 28225306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience.
    Brunelli VL; Russo G; Bertelloni S; Gargantini L; Balducci R; Chiesa L; Livieri C; De Sanctis C; Einaudi S; Virdis R; Saggese G; Chiumello G
    J Pediatr Endocrinol Metab; 2003 Mar; 16 Suppl 2():277-83. PubMed ID: 12729404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: final height in 27 patients with the classical form].
    Lemos-Marini SH; Guerra-Júnior G; Morcillo AM; Baptista MT; Silva LO; Maciel-Guerra AT
    Arq Bras Endocrinol Metabol; 2005 Dec; 49(6):902-7. PubMed ID: 16544012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism.
    Cordeiro GV; Silva IN; Goulart EM; Chagas AJ; Kater CE
    Arq Bras Endocrinol Metabol; 2013 Mar; 57(2):126-31. PubMed ID: 23525290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
    Deslauriers JR; Lenz AM; Root AW; Diamond FB; Bercu BB
    J Pediatr Endocrinol Metab; 2012; 25(9-10):977-81. PubMed ID: 23426829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
    Aycan Z; Ocal G; Berberoglu M; Cetinkaya E; Adiyaman P; Evliyaoglu O
    J Pediatr Endocrinol Metab; 2006 Mar; 19(3):245-51. PubMed ID: 16607925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overestimation of final height prediction in patients with classical congenital adrenal hyperplasia using the Bayley and Pinneau method.
    Bonfig W; Schwarz HP
    J Pediatr Endocrinol Metab; 2012; 25(7-8):645-9. PubMed ID: 23155688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth pattern and final height in 21-hydroxylase deficiency.
    Bajpai A; Pandey RM; Kabra M; Menon PS
    Indian Pediatr; 2007 Oct; 44(10):771-3. PubMed ID: 17998577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort.
    Sarafoglou K; Addo OY; Turcotte L; Otten N; Wickremasinghe A; Pittock S; Kyllo J; Lteif AN; Himes JH; Miller BS
    J Pediatr; 2014 May; 164(5):1141-1146.e1. PubMed ID: 24560184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
    Bonfig W; Schwarz HP
    Horm Res Paediatr; 2011; 75(4):264-8. PubMed ID: 21196707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.